Trevi Therapeutics Inc (OQ:TRVI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 195 Church St Fl 14
NEW HAVEN CT 06510-2009
Tel: N/A
Website: www.trevitherapeutics.com
IR: See website
<
Key People
David P. Meeker
Chairman of the Board
Jennifer L. Good
President, Chief Executive Officer, Co-Founder, Director
Thomas R. Sciascia
Co-Founder, Chief Medical Officer
Christopher J. Seiter
Chief Financial Officer
Helena Brett-Smith
Chief Development Officer
 
Business Overview
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson's disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company's nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.
Financial Overview
For the three months ended 31 March 2020, Trevi Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 38% to $8.5M. Higher net loss reflects Research and development - Balancing val increase of 79% to $5.9M (expense), General and administrative - Balancing v increase of 47% to $2M (expense), Stock-based compensation expense increase from $124K to $637K (expense).
Employees: 17 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$30.43M as of Mar 31, 2020
Net annual income (TTM): -$29.08M as of Mar 31, 2020
Free cash flow (TTM): -$23.67M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,834,570 as of Apr 16, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization